HAE – Haemonetics Corporation

HAE — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

4.32

Margin Of Safety %

Put/Call OI Ratio

0.21

EPS Next Q Diff

EPS Last/This Y

1.91

EPS This/Next Y

0.55

Price

54.02

Target Price

80.2

Analyst Recom

1.91

Performance Q

-9.17

Upside

-17.3%

Beta

0.5

Ticker: HAE

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-13	HAE	59.24	0.21	0.00	3484
2026-04-14	HAE	60.48	0.21	0.00	3489
2026-04-15	HAE	61.93	0.21	0.03	3509
2026-04-16	HAE	60.19	0.21	1.25	3524
2026-04-17	HAE	61.61	0.21	0.57	3533
2026-04-20	HAE	61.14	0.19	999.99	3420
2026-04-21	HAE	60.2	0.19	0.00	3420
2026-04-22	HAE	61.1	0.18	0.00	3440
2026-04-23	HAE	59.62	0.18	999.99	3500
2026-04-24	HAE	60	0.18	1.00	3503
2026-04-27	HAE	60.48	0.18	999.99	3511
2026-04-28	HAE	59.81	0.18	999.99	3511
2026-04-29	HAE	59.01	0.18	0.20	3512
2026-04-30	HAE	60.07	0.18	0.15	3505
2026-05-01	HAE	59.27	0.18	999.99	3519
2026-05-04	HAE	55.35	0.19	1.92	3521
2026-05-05	HAE	55.63	0.20	1.00	3577
2026-05-06	HAE	52.62	0.20	0.60	3582
2026-05-07	HAE	54.36	0.21	0.10	3670
2026-05-08	HAE	55.13	0.21	0.57	3708
2026-05-11	HAE	52.22	0.21	0.19	3720
2026-05-12	HAE	54	0.21	0.00	3719
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-13	HAE	59.28	2.5	38.1	4.95
2026-04-14	HAE	60.49	2.5	35.3	4.95
2026-04-15	HAE	61.95	2.5	36.1	4.95
2026-04-16	HAE	60.13	2.5	24.5	4.95
2026-04-17	HAE	61.61	2.6	36.2	4.95
2026-04-20	HAE	61.24	2.6	29.5	4.95
2026-04-21	HAE	60.19	2.6	27.4	4.95
2026-04-22	HAE	61.13	2.6	34.2	4.95
2026-04-23	HAE	59.65	2.6	25.6	4.95
2026-04-24	HAE	59.97	2.6	32.1	4.95
2026-04-27	HAE	60.47	2.6	32.8	4.95
2026-04-28	HAE	59.81	2.6	28.5	4.95
2026-04-30	HAE	60.06	2.6	34.7	4.95
2026-05-01	HAE	59.37	2.6	28.3	4.95
2026-05-04	HAE	55.31	2.6	16.5	4.95
2026-05-05	HAE	55.65	2.6	32.1	4.95
2026-05-06	HAE	52.61	2.6	19.3	4.95
2026-05-07	HAE	54.30	2.6	37.3	4.95
2026-05-08	HAE	55.18	2.6	34.0	4.95
2026-05-11	HAE	52.23	2.6	19.8	4.95
2026-05-12	HAE	54.02	1.3	37.9	5.24
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-13	HAE	0.21	-5.54	4.53
2026-04-14	HAE	0.21	-5.54	4.53
2026-04-15	HAE	0.21	-5.54	4.53
2026-04-16	HAE	0.21	-5.54	4.53
2026-04-17	HAE	0.21	-5.54	4.53
2026-04-20	HAE	0.21	-5.51	4.53
2026-04-21	HAE	0.21	-5.51	4.53
2026-04-22	HAE	0.21	-5.51	4.53
2026-04-23	HAE	0.21	-5.51	4.53
2026-04-24	HAE	0.21	-5.51	4.53
2026-04-27	HAE	0.21	-4.37	4.36
2026-04-28	HAE	0.21	-4.37	4.36
2026-04-29	HAE	0.21	-4.37	4.36
2026-04-30	HAE	0.21	-4.37	4.36
2026-05-01	HAE	0.21	-4.37	4.36
2026-05-04	HAE	0.21	-5.03	4.36
2026-05-05	HAE	0.21	-5.03	4.36
2026-05-06	HAE	0.21	-5.03	4.36
2026-05-07	HAE	0.21	-5.03	4.36
2026-05-08	HAE	0.21	-5.03	4.36
2026-05-11	HAE	0.21	-2.59	4.36
2026-05-12	HAE	0.21	-2.59	4.32
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

1.11

Avg. EPS Est. Next Quarter

1.29

Insider Transactions

0.21

Institutional Transactions

-2.59

Beta

0.5

Average Sales Estimate Current Quarter

331

Average Sales Estimate Next Quarter

343

Fair Value

72.26

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

44.9

Max Drawdown 5-Year %

-51

Target Price

80.2

P/E

26.58

Forward P/E

9.37

PEG

1.14

P/S

1.88

P/B

2.77

P/Free Cash Flow

9.64

EPS

2.03

Average EPS Est. Cur. Y

5.24

EPS Next Y. (Est.)

5.79

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

7.29

Relative Volume

1.26

Return on Equity vs Sector %

-7.6

Return on Equity vs Industry %

7.5

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

0.3

EBIT Estimation

37.9

◆ HAE Healthcare

$54.01

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

15/25

Volume

1/15

Valuation

20/20

TP/AR

1/10

Options

6/10

RSI

40.3

Range 1M

27.3%

Sup Dist

5.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

12/30

Estimates

6/20

Inst/Vol

2/15

Options

7/10

EPS Yr

5.3%

EPS NY

10.5%

52W%

17.3%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟢 BUY +87.7% upside

Quality

12/30

Valuation

26/30

Growth

7/25

Stability

6/10

LT Trend

1/5

Upside

+87.7%

Quality

MoS

34%

Haemonetics Corporation

Sector: Healthcare

Industry: Medical Devices

Employees:

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

HAE

Latest News

—

Caricamento notizie per HAE…

stock quote shares HAE – Haemonetics Corporation Stock Price stock today

news today HAE – Haemonetics Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch HAE – Haemonetics Corporation yahoo finance google finance

stock history HAE – Haemonetics Corporation invest stock market

stock prices HAE premarket after hours

ticker HAE fair value insiders trading

HAE – Haemonetics Corporation

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: HAE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y